Home > Insider Trading > Filing (0001325812-14-000029)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1492749	Laurence Reid	300 Third Street Cambridge MA 02142	Svp, Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-05-19	2,500	$7.10	6,405	No	4	M	Direct
Common Stock	Acquisiton	2014-05-19	11,000	$9.14	17,405	No	4	M	Direct
Common Stock	Disposition	2014-05-19	2,600	$57.07	14,805	No	4	S	Direct
Common Stock	Disposition	2014-05-19	10,900	$58.01	3,905	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2014-05-19	2,500	$0.00	2,500	$7.10
Common Stock	Stock Option (right to buy)	Disposition	2014-05-19	11,000	$0.00	11,000	$9.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,500		2021-11-30	No	4	M	Direct
16,589		2020-12-08	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,719	Indirect	by Managed Account

Footnotes

The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2013.
Sale prices ranged from from $56.70 to $57.66.
Sale prices ranged from from $57.75 to $58.30.
The reporting person owns 1,719 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.